AB0844 ARTERIAL ISCHEMIC EVENTS AND VENOUS THROMBOSIS IN SYSTEMIC SCLEROSIS: DATA FROM A MONO-CENTRIC STUDY

Background Systemic sclerosis is a systemic autoimmune disease characterized by vasculopathy (Raynaud phenomena), pulmonary arterial hypertension (PAH), and renal crisis), fibrosis of skin visceral organs (notably the gut, heart, lungs), musculoskeletal inflammation (joints, muscles, tendons) [1]. Inflammation drives atherosclerosis contributes to cardiovascular (CV) [2] . A few studies have examined incidence individual macrovascular manifestations such as myocardial infarction, stroke, peripheral artery disease, venous thromboembolism [3-4-5]. Objectives Our aim estimate ischemic events thrombosis rates SSc in our database. We also investigated underlying classical risk factors for (VTE ) unprovoked (deep emboli not associated with cancer, recent surgery, hospitalization, fracture pregnancy) ASCVD (myocardial infarction stroke). Methods In retrospective cohort patients between 2005 2017, stroke), thrombosis, Factor (Hyperlipidemia, Smoking, Diabetes, hypertension, abdominal obesity), thromboembolism, well cardiac, cutaneous immunological characteristics were assessed. Results The study population comprised 212 (86 % female) diagnosis SSc. identified total 7 (3%) 26 (12%) respectively an only or 6 additional both event during median 10(5-34) (0-55) years follow-up. Venous (VT) present (12 %), active historic neoplasia 4 (15%) VT. comparison patient without VT, 20 (11%) neoplasia. Arterial are most frequent female sex n=6 %) all (100%) limited sclerosis, antinuclear antibodies Raynaud phenomena, but no difference control group thrombotic events. prevalence disorders was found be higher than diffuse sclerosis. tobacco use, alcohol increase thromboembolic presence other tissue significant (p>0.0003) rate among without. Further adjustment medications (aspirin, NSAIDs, glucocorticoids, statins, oral anticoagulants, platelet inhibitors) comorbidities yielded results similar main analyses, except stroke. Conclusion this monocentric study, greater risks events, mortality There statistic comorbidity References [1]Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score predictor correlate outcome Arthritis Rheum. 2000; 43:2445–2454 [2]Wollheim FA. Classification Visions reality Rheumatology. 2005;44:1212–6. [3]Ranque B, Mouthon L. Geoepidemiology Autoimmun Rev. 2010;9: A311–8 [4]Singer DE, Albers GW, Dalen JE, Antithrombotic therapy atrial Fibrillation. American College Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest. 2008;133(6 Suppl):546S–592S [5]Becker RC, Meade TW, Berger PB, primary secondary prevention coronary disease. Suppl):776S–814S Acknowledgements: NIL. Disclosure Interests None Declared.